Objective: To determine the cost effectiveness, from the Brazilian Ministry of Health viewpoint, of three antidepressant classes for major depressive disorder (MDD), and the budget impact of introducing serotonin-noradrenaline (norepinephrine) reuptake inhibitors (SNRIs) into the current...

Objective: To describe the pharmacological treatment for major depression under the conditions of routine Italian public mental health facilities, assess its costs, and study its main predictors according to a societal perspective. Design: This was a prospective multicentre observational study...

Objective: To estimate the cost effectiveness of different classes of antidepressants in the UK National Health Service. Design, patients and interventions: The use of the serotonin (5-hydroxytryptamine; 5-HT) and noradrenaline (norepinephrine) reuptake inhibitor (SNRI) venlafaxine was compared...

Background: Selective serotonin reuptake inhibitors (SSRIs) and serotonin-noradrenaline reuptake inhibitors (SNRIs) are approved for the treatment of major depressive disorder (MDD). The allosteric SSRI escitalopram has been shown to be at least as clinically effective as the SNRIs venlafaxine...

Depression is under-detected, but is treatable and relapses can be prevented. Living with depression, whether acute or chronic, has consequences for quality of life, premature end of life, and productive life. Thoughtful and strategic quality improvement (QI) programs offer one avenue for...

With increasing chronic disease and disability burden as a result of the aging of populations worldwide, cost estimates of disease and disability are important in determining: 1. the most cost-effective methods in delivering healthcare in order to maximise resources; and 2. health policies and...

Disease management has the potential to make great improvements in the treatment of depressive disorders, yielding benefits for both the patients receiving treatment and their employers. This review of the medical and business literature found that this potential is still largely untapped, with...

Objective: The purpose of this study was to evaluate the treatment patterns and success rates with antidepressants utilized by patients in a managed care organization (MCO). Methods: Data were extrapolated from a claims database from an MCO with 225 000 members. Treatment patterns were...

Objective: The purpose of this study was to evaluate the use of antidepressants through use of mutually exclusive disease indications using a managed care database. Design and setting: A claims database from a 225 000 member managed care organisation was used for the study. A hierarchy of...

Depression remains under-recognised and under-treated despite it being more disabling than any other medical disorder and the availability of effective protocol-based psychotherapy and pharmacotherapy treatments. Prevailing psychotherapy seldom employs evidence-based treatments, continuing...